✦ LIBER ✦

Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia

✍ Scribed by Hayes M. Dansky; Daniel Bloomfield; Patrice Gibbons; Sherry Liu; Christine McCrary Sisk; Diane Tribble; James M. McKenney; Thomas W. Littlejohn III; Yale Mitchel

Book ID: 116192570
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 212 KB
Volume: 162
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2011.07.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of the cholesteryl e

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia

✍ Teramoto, Tamio; Shirakawa, Masayoshi; Kikuchi, Masashi; Nakagomi, Mariko; Tamur 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 379 KB

Efficacy and safety of the cholesteryl e

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

✍ Daniel Bloomfield; Gary L. Carlson; Aditi Sapre; Diane Tribble; James M. McKenne 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 450 KB

EFFICACY AND SAFETY OF THE CHOLESTERYL E

EFFICACY AND SAFETY OF THE CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR ANACETRAPIB AS MONOTHERAPY AND COADMINISTERED WITH ATORVASTATIN IN JAPANESE PATIENTS WITH DYSLIPIDEMIA

✍ Teramoto, Tamio; Numaguchi, Hirotaka; Shirakawa, Masayoshi; Kikuchi, Masashi; Na 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 89 KB

Evaluation of Lipids, Drug Concentration

Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease

✍ Gotto, Antonio M.; Cannon, Christopher P.; Li, Xiujiang Susie; Vaidya, Sanskruti 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 753 KB